HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Recombinant Fusion Proteins

Subscribe to New Research on Recombinant Fusion Proteins

Recombinant proteins produced by the GENETIC TRANSLATION of fused genes formed by the combination of NUCLEIC ACID REGULATORY SEQUENCES of one or more genes with the protein coding sequences of one or more genes.

Also Known As:

Chimeric Proteins, Recombinant; Hybrid Proteins, Recombinant; Recombinant Chimeric Proteins; Recombinant Hybrid Proteins; Proteins, Recombinant Chimeric; Proteins, Recombinant Fusion; Proteins, Recombinant Hybrid; Fusion Proteins, Recombinant

Networked: 34 relevant articles (2 outcomes, 3 trials/studies) for this Bio-Agent, Comments

Relationship Network

Bio-Agent Context: Research Results

Amino Acids, Peptides, and Proteins
- Proteins: 58343
  - Recombinant Proteins: 500
    - Recombinant Fusion Proteins: 34

Experts

1.	Hermida, Lisset: 4 articles (12/2008 - 04/2006)
2.	Guzmán, María G: 4 articles (12/2008 - 04/2006)
3.	Guillén, Gerardo: 3 articles (12/2008 - 04/2006)
4.	Bernardo, Lidice: 3 articles (12/2008 - 01/2008)
5.	Rosario, Delfina: 3 articles (11/2008 - 04/2006)
6.	Prado, Irina: 3 articles (11/2008 - 04/2006)
7.	Martínez, Rafael: 3 articles (11/2008 - 04/2006)
8.	López, Carlos: 3 articles (11/2008 - 04/2006)
9.	Alvarez, Mayling: 3 articles (11/2008 - 04/2006)
10.	Santana, Emidalys: 2 articles (12/2008 - 11/2008)

Related Diseases

1.	Neoplasms (Cancer) 01/01/1998 - "However, the antitumor effect of hTNF-Ly-2.1 on E3 cells in vivo was marginal with some tumor growth retardation at day 1-3. The results of these in vitro and in vivo studies on chemically conjugated h-TNF-MoAb will be helpful in the design of novel recombinant fusion proteins for targeting the biologic activity of TNF to tumours." 02/01/2002 - "These recombinant fusion proteins provide a novel class of anti-cancer agents that will enter clinical trials in the next several years." 05/18/2005 - "Specific occlusion of murine and human tumor vasculature by VCAM-1-targeted recombinant fusion proteins." 01/01/2007 - "Thus the recombinant fusion proteins could serve as cell-permeable HIF-1 antagonists, function as both inhibitors of tumor angiogenesis and tumor radiosensitizers, and would be widely used in clinical settings to improve tumor response to radiotherapy." 08/01/2004 - "Recombinant fusion proteins IL-13 cytotoxin (IL13-PE38QQR or IL13-PE38) have been developed to directly target IL-13R-expressing cancer cells. " Order ALL the reference details at left...
2.	Malaria 06/01/1992 - "Protection of Aotus monkeys from malaria infection by immunization with recombinant hybrid proteins." 03/01/1993 - "Conservation of antigen components from two recombinant hybrid proteins protective against malaria." Order ALL the reference details at left...
3.	Cutaneous T-Cell Lymphoma (Lymphoma, T Cell, Cutaneous) 08/01/1996 - "While several recombinant fusion proteins have entered or will shortly begin Phase I/II human clinical trials, the first of these fusion proteins is currently being evaluated in Phase III human clinical trials for the treatment of cutaneous T cell lymphoma." Order ALL the reference details at left...
4.	Dengue (Dengue Fever) 11/01/2008 - "Recombinant fusion proteins containing the aa 286-426 of the dengue envelope protein fused to P64k protein from Neisseria meningitidis have been previously reported. " 01/01/2008 - "Anamnestic antibody response after viral challenge in monkeys immunized with dengue 2 recombinant fusion proteins." 04/12/2006 - "We have previously reported the construction and evaluation in mice of recombinant fusion proteins formed by a fragment (aa 286-426) of the dengue envelope protein and the P64k protein from Neisseria meningitidis. " 09/01/1990 - "The antigenic structures of the envelope protein, E, and the non-structural protein, NS1, of dengue type 1 virus (DEN1) have been studied in the form of recombinant fusion proteins expressed in Escherichia coli. " 12/01/2008 - "Here, the antigenic specificity of the recombinant fusion proteins containing aa 286-426 of the dengue envelope protein fused to P64k from Neisseria meningitidis and the cross-reactive antibody response induced in immunized mice and monkeys were evaluated. " Order ALL the reference details at left...
5.	Glioma (Gliomas) 04/01/1998 - "To determine the domains responsible for glioma migration and attachment, we produced recombinant fusion proteins that collectively span the majority of the molecule including its epidermal growth factor-like repeats, fibronectin type III repeats and fibrinogen domain. " 11/01/1993 - "To identify potential cell surface receptors for chicken cytotactin (CT), we have characterized the ability of recombinant fusion proteins spanning the proximal fibronectin (FN) type III repeats of the molecule to support attachment of glioma and carcinoma cell lines. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Antigens
2.	Proteins (Proteins, Gene)
3.	Epitopes
4.	Antibodies
5.	Complementary DNA (cDNA)
6.	Cytokines
7.	Fibronectins (Fibronectin)
8.	Autoantibodies
9.	Tenascin
10.	Vascular Cell Adhesion Molecule-1 (Vascular Cell Adhesion Molecule 1)

Related Therapies and Procedures

1.	Therapeutics
2.	Radiotherapy
3.	Biological Therapy

blog comments powered by Disqus

TREATMENT OPTIONS
for Neoplasms,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 20715 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>